pioglitazone has been researched along with Heart Diseases in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone has been demonstrated to have beneficial effects on cardiovascular outcomes." | 5.38 | Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| "Pioglitazone treatment might suppress in-stent neointimal proliferation and reduce incidence of TLR after PCI in patients with T2DM." | 2.74 | A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). ( Fitzgerald, PJ; Honda, Y; Ikeno, F; Ito, A; Kataoka, T; Kobayashi, Y; Okura, H; Sakanoue, Y; Shimeno, K; Taguchi, H; Takagi, T; Tamita, K; Toda, I; Waseda, K; Yamamuro, A; Yamasaki, M; Yanagi, S; Yoshikawa, J; Yoshiyama, M, 2009) |
| "Standard treatment of obesity with lifestyle interventions including diet, exercise, and behavioral modification has been shown to improve NASH as well as reduce cardiovascular dysfunction." | 2.58 | Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. ( Kumar, RB; Mathews, SE; Shukla, AP, 2018) |
| "Pioglitazone has been demonstrated to have beneficial effects on cardiovascular outcomes." | 1.38 | Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mathews, SE | 1 |
| Kumar, RB | 1 |
| Shukla, AP | 1 |
| Takagi, T | 1 |
| Okura, H | 1 |
| Kobayashi, Y | 1 |
| Kataoka, T | 1 |
| Taguchi, H | 1 |
| Toda, I | 1 |
| Tamita, K | 1 |
| Yamamuro, A | 1 |
| Sakanoue, Y | 1 |
| Ito, A | 1 |
| Yanagi, S | 1 |
| Shimeno, K | 1 |
| Waseda, K | 1 |
| Yamasaki, M | 1 |
| Fitzgerald, PJ | 1 |
| Ikeno, F | 1 |
| Honda, Y | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Nissen, SE | 1 |
| Elrashidy, RA | 1 |
| Asker, ME | 1 |
| Mohamed, HE | 1 |
| Sakamoto, A | 1 |
| Hongo, M | 1 |
| Furuta, K | 1 |
| Saito, K | 1 |
| Nagai, R | 1 |
| Ishizaka, N | 1 |
| Thiemermann, C | 1 |
| D'Arrigo, T | 1 |
1 review available for pioglitazone and Heart Diseases
| Article | Year |
|---|---|
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet; Exercise; Heart Diseases; Humans; Life Style; Non-al | 2018 |
1 trial available for pioglitazone and Heart Diseases
| Article | Year |
|---|---|
A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Glucose; California; Cell Proliferation; Coronary Angiog | 2009 |
6 other studies available for pioglitazone and Heart Diseases
| Article | Year |
|---|---|
Pioglitazone to reduce restenosis after bare-metal stent placement?
Topics: Angioplasty, Balloon, Coronary; Cell Proliferation; Coronary Restenosis; Diabetes Mellitus, Type 2; | 2009 |
Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Di | 2012 |
Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Blood Pressure; Diastole; Disease Models, Animal; Heart Diseases; Hypertens | 2013 |
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; | 2004 |
Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Topics: Animals; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Heart Diseases; Humans; | 2004 |
Glitazones and your heart, revisited.
Topics: Heart Diseases; Heart Failure; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |